- 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
-
This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
- -
-
-
- Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
-
This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein A is C1-6alkylene or —NR1—; Z is C(═L)R2, or SO2R3; U is CH or N; W and Y are inde
- -
-
-
- Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents
-
This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is tetrazolyl optionally substituted with a substituent selected from C1-4 alkyl and halosubstituted C1-4 alkyl;A is C1-6 alkylene; Q is selected from the following groups: (a) optionally substituted phenyl; (b) an optionally substituted, partially saturated, fully saturated or fully unsaturated five to six membered monocyclic group having one to three heteroatoms; and (c) an optionally substituted, bicyclic group consisting of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings independently and optionally having one to four heteroatoms; X is halogen, C1-4 alkyl, halosubstituted C1-4 alkyl, OH, C1-4 alkoxy or the like; and n is 0, 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
- -
-
-